Gene therapy of cancer : Translational approaches from preclinical studies to clinical implementation /: Translational approaches from preclinical studies to clinical implementation. ([2002])

• Record Type: Book
• Further Information: Note: Edited by Edmund C. Lattime, Stanton L. Gerson.
• Editors: Lattime, Edmund C, 1951-; Gerson, Stanton L
• Contents: Contributors; ; Preface; ; Part I Vectors for Gene Therapy of Cancer; ; 1. Retroviral Vector Design for Cancer Gene Therapy; ; I. Introduction; ; II. Applications for Retroviral Vectors in Oncology; ; III. Biology of Retroviruses; ; IV. Principles of Retroviral Vector Systems; ; V. Advances in Retroviral Vector Tailoring; ; VI. Outlook; ; References; ; 2. Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy; ; I. Introduction; ; II. Advantages and Disadvantages of Infectious, Viral-Based Vectors for Human Gene Therapy; ; III. Rationale for Considering Noninfectious, Plasmid-Based Expression Systems; ; IV. Gene Transfer Technologies for Plasmid-Based Vectors: Preclinical Models and Clinical Cancer Gene Therapy Trials; ; V. Plasmid Expression Vectors; ; VI. Future Directions; ; References; ; 3. Parvovirus Vectors for the Gene Therapy of Cancer; ; I. Introduction; ; II. Biology of Parvoviridae and Vector Development; ; III. Applications of Recombinant Parvovirus Vectors to Cancer Gene Therapy; ; IV. Perspectives, Problems, and Future Considerations; ; References; ; 4. Antibody-Targeted Gene Therapy; ; I. Introduction; ; II. Background: Monoclonal Antibodies and Cancer Therapy; ; III. Recent Advances: Monoclonal-Antibody-Mediated Targeting and Cancer Gene Therapy; ; IV. Future Directions; ; References; ; 5. Ribozymes in Cancer Gene Therapy; ; I. Introduction; ; II. Ribozyme Structures and Functions; ; III. Cancer Disease Models for Ribozyme Application; ; IV. Challenges and Future Directions; ; References; ; 6. The Advent of Lentiviral Vectors: Prospects for Cancer Therapy; ; I. Introduction; ; II. Structure and Function of Lentiviruses; ; III. Features that Distinguish Lentiviral from Oncoretroviral Vectors; ; IV. Manufacture of Lentiviral Vectors; ; V. Possible Applications of Lentiviral Vectors in Cancer Therapy; ; VI. Conclusions; ; References; ; Part II Immune Targeted Gene Therapy; ; 7. Immunologic Targets for the Gene Therapy of Cancer; ; I. Introduction; ; II. Cellular (T-Lymphocyte-Mediated) Versus Humoral (Antibody-Mediated) Immune Responses to Tumor Cells; ; III. Response of CD4+ and CD8+ T Lymphocytes to Tumor Antigens Presented in the Context of Molecules Encoded by the Major Histocompatibility Complex; ; IV. Response of Tumor-Bearing Individuals to Tumor Antigens; ; V. Tumor-Associated Peptides as Candidate Targets for Tumor-Specific Lymphocytes; ; VI. Immunotherapeutic Strategies for the Treatment of Cancer; ; VII.Conclusions; ; References; ; Part IIa Vaccine Strategies; ; 8. Development of Epitope-Specific Immunotherapies for Human Malignancies and Premalignant Lesions Expressing Mutated ras Genes; ; I. Introduction; ; II. Cellular Immune Response and Antigen Recognition; ; III. Pathways of Antigen Processing, Presentation, and Epitope Expression; ; IV. T-Lymphocyte Subsets; ; V. ras Oncogenes in Neoplastic Development; ; VI. Cellular Immune Responses Induced by ras Oncogene Peptides; ; VII. Identification of Mutant ras CD4+ and CD8+ T-Cell Epitopes Reflecting Codon 12 Mutations; ; VIII. Anti-ras Immune System Interactions: Implications for Tumor Immunity and Tumor Escape; ; IX. Paradigm for Anti-ras Immune System Interactions in Cancer Immunotherapy; ; X. Future Directions; ; References; ; Part IIb Dendritic Cell-Based Gene Therapy; ; 9. Introduction to Dendritic Cells; ; I. Introduction; ; II. Features of Dendritic Cells; ; III. Dendritic Cell Subsets; ; IV. Functional Heterogeneity of Dendritic Cell Subsets; ; V. Dendritic Cells in Tumor Immunology; ; VI. Dendritic Cells and Gene Therapy; ; VII. Conclusions; ; References; ; 10. DNA and Dendritic Cell-Based Genetic Immunization Against Cancer; ; I. Introduction; ; II. Background; ; III. Recent Advances: Methods of Genetic Immunization; ; IV. Preclinical Development and Translation to the Clinic; ; V. Proposed and Current Clinical Trials; ; VI. Future Directions; ; References; ; 11. RNA-Transfected Dendritic Cells as Immunogens; ; I. Introduction; ; II. Advantages of Loading Dendritic Cells with Genetic Material; ; III. Viral Versus Nonviral Methods of Gene Transfer 200; ; IV. RNA Versus DNA Loading of Dendritic Cells; ; V. RNA Loading of Dendritic Cells; ; VI. Amplification of RNA Used to Load Dendritic Cells; ; VII. Uses of RNA-Loaded Dendritic Cells; ; VIII. Future Directions; ; References; ; PART IIc CYTOKINES AND CO-FACTORS; ; 12. In Situ Immune Modulation Using Recombinant Vaccinia Virus Vectors: Preclinical Studies to Clinical Implementation; ; I. Introduction; ; II. Generation of Cell-Mediated Immune Responses; ; III. Cytokine Gene Transfer Studies in Antitumor Immunity; ; IV. In Situ Cytokine Gene Transfer to Enhance Antitumor Immunity; ; V. Future Directions; ; VI. Conclusions; ; References; ; 13. The Use of Particle-Mediated Gene Transfer for Immunotherapy of Cancer; ; I. Introduction; ; II. Background; ; III. Recent Advances; ; IV. Issues Regarding Evaluation in Clinical Trials; ; V. Recent Clinical Trials; ; VI. Potential Novel Uses and Future Directions; ; References; ; PART IId GENETICALLY MODIFIED EFFECTOR CELLS FOR IMMUNE-BASED IMMUNOTHERAPY; ; 14. Applications of Gene Transfer in the Adoptive Immunotherapy of Cancer; ; I. Introduction; ; II. Use of Gene-Modified Tumors to Generate Antitumor-Reactive T Cells; ; III. Genetic Manipulation of T Cells to Enhance Antitumor Reactivity; ; IV. Genetic Modulation of Dendritic Cells; ; V. Summary; ; References; ; 15. Update on the Use of Genetically Modified Hematopoietic Stem Cells for Cancer Therapy; ; I. Introduction; ; II. Human Hematopoietic Stem Cells as Vehicles of Gene Transfer; ; III. Preclinical Studies of Gene Transfer into Hematopoietic Stem Cells; ; IV. Applications of Genetically Manipulated Hematopoietic Stem Cells to the Therapy of Human Cancer; ; V. Conclusions; ; References; ; Part III Oncogene-Targeted Gene Therapy; ; 16. Clinical Applications of Tumor-Suppressor Gene Therapy; ; I. Introduction; ; II. p53; ; III. BRCA1; ; IV. Onyx-015 Adenoviruses; ; V. Summary and Future Work; ; References; ; 17. Cancer Gene Therapy with Tumor Suppressor Genes Involved in Cell-Cycle Control; ; I. Introduction; ; II. p21WAF1/CIP1; ; III. p16INK4; ; IV. Rb; ; V. p14ARF; ; VI. p27Kip1; ; VII. E2F-1; ; VIII. PTEN; <b
• Edition: Second edition
• Publisher Details: San Diego : Academic Press
• Publication Date: 2002
• Extent: 1 online resource, illustrations
• Subjects: 616.994042; Cancer -- Gene therapy; Cancer -- Immunotherapy
• Languages: English
• ISBNs: 9780080491363; 0080491367
• Related ISBNs: 0124375510
• Notes: Note: Includes bibliographical references and index.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.